Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood clues could unlock new ewing sarcoma treatments

NCT ID NCT07685405

Knowledge-focused Sponsor: Istituto Ortopedico Rizzoli Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study examines blood samples from people with Ewing sarcoma to find circulating biomarkers—substances that might signal the presence or behavior of the cancer. Researchers will compare samples from patients and healthy volunteers to identify markers that could help validate new treatments. The goal is to lay groundwork for more targeted therapies in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could point toward new ways to detect or treat Ewing sarcoma by using blood-based markers.
What could go wrong
This is a very small, early feasibility study with only 16 participants, so findings may not apply broadly or lead directly to treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 16 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Apr 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study aims to enroll patients of any gender who are being treated at the Rizzoli Orthopedic Institute in the following departments: Orthopedic and Traumatology Clinic III (with a primary focus on oncology), General and Thoracic Surgery (for both cancer and non-cancer patients), and Osteoncology, Bone and Soft Tissue Sarcomas, and Innovative Therapies (for cancer patients only).

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for cancer patients * Male and female patients of any age diagnosed with Ewing sarcoma. * Signed, study-specific informed consent form for the BIOVES study (cancer patients) Inclusion criteria for non-cancer patients * Male and female patients of legal age without a cancer diagnosis. * Signed, study-specific informed consent form for the BIOVES study (non-cancer patients) Exclusion Criteria: Patients who do not meet all inclusion criteria \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sarcoma, Ewing are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sarcoma, Ewing

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istituto ortopedico Rizzoli Laboratorio di Ricerc Oncologica e Genomica funzioanle

    RECRUITING

    Bologna, BO, 40136, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.